TEVA's only goal : HIGH MARGIN on "generic compunds" through unique "patented" delivery
Knowing the inflection point is near, we finally see two different insiders come out and buy some stock with their real cash in the open market. They cant sell for 6 months and I think we will see some more insider buying as this thing is about to become a real comppany.
Resistance is above $10 - You have no spec premium at these levels (ie - $5) and practically no downside risk. We are getting ready to haul #$%$
I really hope they don't get bought out for atleast another year. The thought of what the market cap could be is exponentially higher than current valuation. Given that the US milestones for Adasuve alone are in the $200M range and we are trading at a market cap of $90M makes no sense at all to me. Especially given the company has $30M+ in cash, and that does not even factor in milestones for the remainder of the world and incremental royalites earned on every sale. Add onto that new compounds for migraines, break-through pain, epilepsy, ED, and many more and the sky is the limit. Can modestly see a Market Cap of $1B+ in 2-3 years if this story plays out nicely.